This study reports on two open-label Phase 1/2 trials assessing the safety and tolerability of subretinal transplantation of human embryonic stem cell-derived retinal pigment epithelium (hESC-RPE) in nine patients with atrophic age-related macular degeneration (AMD) and nine with Stargardt's macular dystrophy. Patients received varying doses (50,000 to 150,000 cells) and
